GlaxoSmithKline is developing a new treatment for severe asthma and is filing for US and European applications for the injectable mepolizumab.

The treatment works by blocking the protein interleukin-5 and thus preventing buildups of white blood cells in the lungs that can exacerbate asthma. GSK is angling to get the drug approved as a treatment for sufferers of severe asthma who aren’t getting the relief they need from inhaled therapies.

Read the full story at